FDA and FTC warned CannaAid over website claims that CBD/cannabinoid products prevent or treat COVID-19.
What happened
FDA reviewed https://www.cannaaidshop.com/ on October 5, 2022, and FTC reviewed it on October 7, 2022. The site offered CBD and cannabinoid products with claims that they could mitigate, prevent, treat, diagnose, or cure COVID-19. FDA said the products were unapproved new drugs (sold without FDA approval) and misbranded drugs (drug labeling/claims violations).
What FDA found
The CBD/cannabinoid products are unapproved new drugs because they were sold with COVID-19 treatment or prevention claims without FDA approval.
section 505(a) of the FD&C Act, 21 U.S.C. § 355(a)The products are misbranded drugs because their labeling or claims violate the FD&C Act.
section 502 of the FD&C Act, 21 U.S.C. § 352The company may not ship these products across state lines.
sections 301(a) and (d) of the FD&C Act, 21 U.S.C. § 331(a) and (d)The website made COVID-19 prevention or treatment claims without competent and reliable scientific evidence.
FTC Act, 15 U.S.C. § 41 et seq.The company made deceptive COVID-19 treatment, cure, prevention, or mitigation claims that can bring civil penalties.
COVID-19 Consumer Protection Act, Section 1401, Division FF, Consolidated Appropriations Act, 2021, P.L. 116-260
What FDA wants
FDA asks the company to immediately stop selling unapproved products for COVID-19 and, within 48 hours, email the specific steps taken to COVID-19-Task-Force-CDER@fda.hhs.gov; FTC asks for a 48-hour certification that the unsubstantiated claims have ceased.
Who should pay attention
- CBD and hemp product sellers making health claims
- companies marketing supplements with COVID-19 claims
- advertising and compliance teams for wellness brands
This is a summary. Read the original letter on fda.gov.